Vaccine
Volume 27, Issue 36, Pages 4875-5026 (6 August 2009)
http://www.sciencedirect.com/science/journal/0264410X

Cost of routine immunization of young children against rotavirus infection with Rotarix versus RotaTeq
Pages 4930-4937
Derek Weycker, Oleg Sofrygin, Jason E. Kemner, Stephen I. Pelton, GerryOster

Abstract
Using a probabilistic model of the clinical and economic burden of rotavirus gastroenteritis (RVGE), we estimated the expected impact of vaccinating a US birth cohort with Rotarix in lieu of RotaTeq. Assuming full vaccination of all children, use of Rotarix – rather than RotaTeq – was estimated to reduce the total number of RVGE events by 5% and associated costs by 8%. On an overall basis, Rotarix would reduce costs by $77.2 million (95% CI $71.5–$86.5). Similar reductions with Rotarix were estimated to occur under an assumption of incomplete immunization of children.